| Market Capitalization (Millions $) |
13,712 |
| Shares
Outstanding (Millions) |
873 |
| Employees |
467 |
| Revenues (TTM) (Millions $) |
630 |
| Net Income (TTM) (Millions $) |
38 |
| Cash Flow (TTM) (Millions $) |
-256 |
| Capital Exp. (TTM) (Millions $) |
18 |
Hutchmed China Limited
Hutchmed China Limited, commonly known as Hutchison China MediTech, is a biopharmaceutical company headquartered in Hong Kong, China. The company is primarily focused on discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and other medical conditions.
Hutchmed was established in 2000 as a subsidiary of Hutchison Whampoa Limited, a multinational conglomerate. In 2016, Hutchmed was spun off as an independent, publicly traded company listed on the Hong Kong Stock Exchange, raising approximately $100 million in the process.
The company's oncology portfolio consists of several late-stage clinical programs, including sulfatinib, a selective inhibitor of vascular endothelial growth factor receptor (VEGFR), which is being developed for the treatment of advanced neuroendocrine tumors (NETs) and biliary tract cancer (BTC). Hutchmed also has several non-oncology programs, including a late-stage clinical program for the treatment of hyperuricemia and gout.
With a focus on precision medicine, the company aims to develop targeted therapies that can more effectively treat patients while reducing the risk of side effects. Hutchmed has established collaborations with leading academic institutions and pharmaceutical companies in China and internationally to advance its innovative drug discovery and development programs.
Hutchmed has a strong presence in China and has established a commercial infrastructure to support the launch of new products. The company currently has more than 600 employees, including over 200 scientists and researchers working in its R&D facilities in Shanghai, China.
In addition to its drug discovery and development programs, Hutchmed is committed to supporting cancer patients and their families. The company has launched several patient assistance programs in China to provide financial assistance and emotional support to cancer patients.
Overall, Hutchmed is a leading biopharma company with a strong focus on innovative drug discovery and development programs in oncology and other medical areas. The company's dedication to precision medicine and patient-centered care has made it a significant player in the rapidly growing global biopharmaceutical industry.
Company Address: 48th Floor, Cheung Kong Center Central 0
Company Phone Number: 2121 8200 Stock Exchange / Ticker: NASDAQ HCM
|
0.28% 
99.31 %